Skip to content

RNTX RNTX Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$146M+1.4%
Gilead Sciences logo
Gilead SciencesGILD
$218M+4.3%
AbbVie logo
AbbVieABBV
$444M+8.3%
CTO
Citius Oncology, Inc.CTOR
$3.53M+68.9%
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
$1.31M+11.0%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$2.58M+409%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: RNTX’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's stock-based comp?
RNTX (RNTX) reported stock-based comp of $156K in Q1 2026.
How has RNTX's stock-based comp changed year-over-year?
RNTX's stock-based comp decreased by 40.9% year-over-year, from $264K to $156K.
What is the long-term trend for RNTX's stock-based comp?
Over 4 years (2021 to 2025), RNTX's stock-based comp has grown at a -0.4% compound annual growth rate (CAGR), from $2.26M to $2.22M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.